https://www.selleckchem.com/pr....oducts/alflutinib-as
5 (95% CI 11.76-21.32) months compared to 11.3 (95% CI 9.86-15.51) months in CCL5 ; hazard ratio 1.95 (95% CI 1.04-8.65; p = 0.037). CCL5 is an independent prognostic biomarker in LAPC. Given the known role of CCL5 in tumour invasion, metastasis and the induction of an immunosuppressive micro-environment, targeting of CCL5-mediated pathways may offer therapeutic potential in pancreatic cancer. The SCALOP trial was registered with ISRCTN, number 96169987 (registered 29 May 2008). The SCALOP trial was registered with I
Me gusta
Comentario
Compartir
